Aptar Digital Health and SHL Medical enter strategic partnership to optimize the patient experience with self-injectable therapies

SHL Medical and AARDEX Group announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate patient adherence within clinical trials.

Aptar Digital Health, a global leader in digital health solutions (Software as a Medical Device (SaMD) and digital Patient Support Programs), connected devices and disease management, and SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors, and innovative specialty delivery systems, today announced their strategic partnership. The collaboration will extend SHL Medical’s connected device technologies by integrating Aptar Digital Health’s SaMD platform to provide comprehensive solutions to help patients on injectable therapies manage their disease.

Devices designed by SHL such as the Molly Connected Cap, a smart retrofittable add-on for SHL Medical’s market-proven Molly modular platform autoinjector, would benefit from Aptar Digital Health’s SaMD platform to enhance the patient experience by offering an optimized support. The Molly Connected Cap is a quick-to-market patient monitoring solution engineered for compatibility with various medical data systems, IoT devices, and digital health apps for seamless ecosystem integration.

Aptar Digital Health’s SaMD platform offers digital health solutions adapted to the patient’s profile, disease state, and treatment plan to empower them during their treatment journey. Through the partnership, SHL Medical will recommend Aptar Digital Health as one of the trusted digital partners with a large portfolio of regulated digital health solutions spanning multiple therapeutic areas and medical use. Within the framework of SHL Medical’s Alliance Management Program, the partnership will leverage both companies’ capabilities to develop end-to-end solutions for biotech and pharmaceutical industries that would support the enhancement of patient’s experience during self-injection of innovative drugs such as GLP-1, and facilitate patient orientation.

“Embarking on a self-injection therapy and adhering to a consistent injection schedule can pose a significant challenge to patients and affect the active involvement in their treatment journey,” said Sai Shankar, President of Aptar Digital Health. “By joining forces with SHL Medical, a world-class leader in innovative drug delivery systems, we aim to positively and durably change the experience of patients who must self-inject regularly.”

“The increasing need for home-based treatments and the evolving healthcare landscape have created a need for collaborative innovation within the drug delivery industry,” said Ralph Howald, Chief Technical Officer at SHL Medical. “With our combined expertise, the partnership with Aptar Digital Health will serve as the first step to realizing a thoroughly-needed digital ecosystem for injectable drugs, starting with a digital transformation that will impact the end-to-end value chain in the future.”